XEN1101 appears safe and effective for the treatment of focal-onset seizures (FOSs), according to results of a phase 2b study published online Oct. 9 in JAMA Neurology. Jacqueline A. French, M.D., ...

Topline results from RISE3 are expected in H2 2026.

Focal-onset seizures (FOSs) are the most common type of seizure experienced by epileptic individuals. A recent randomized control trial published in JAMA Neurology evaluated the effect of a novel ...

Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures The CORE-VNS 36-month data analysis reaffirms the effectiveness of VNS Therapy ...

Please provide your email address to receive an email when new articles are posted on . XEN1101 is a novel small-molecule selective Kv7.2/Kv7.3 potassium channel opener. A 25 mg dose of XEN1101 ...

FDA has accepted for review the New Drug Application (NDA) for an investigational oral suspension formulation of cenobamate for the treatment of focal seizures in adults. The FDA assigned a ...

Most newly diagnosed patients with focal epilepsy continued to have seizures for a year or more after starting antiseizure medications (ASMs), results from the latest Human Epilepsy Project (HEP) ...

Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies to treat a broad range of rare and ...

Please provide your email address to receive an email when new articles are posted on . Seizure freedom was observed by 12 months and continued past 48 months of the open-label extension. Long-term ...

SALT LAKE CITY (ABC4) — Intermountain Health neurologists are celebrating a major surgical milestone: the 100th use of an ...

Briviact (brivaracetam) is a brand-name drug prescribed to treat partial (focal onset) seizures in adults and children. Briviact comes in several dosage forms and is typically taken twice per day.